Changes of apolipoprotein B molecular weight and immunoreactivity in malondialdehyde-modified low density lipoproteins.
ApoB molecular weight by SDS polyacrylamide gel electrophoresis and its immunoreactivity by either electroimmunoassay or radial immunodiffusion has been recorded in human malondialdehyde-modified low density lipoproteins. Malondialdehyde treatment of LDL leads to a reduction of the typical B-100 band and to the appearance of two heavier peptides that can be designated as B-126 and B-151 according to the centile nomenclature. A significant increase of the height of apoB rockets by electroimmunoassay and of the immunoprecipitates diameter by radial immunodiffusion was also recorded.
D001053:Apolipoproteins / Q000097:blood* / Q000276:immunology; D001055:Apolipoproteins B; D001161:Arteriosclerosis / Q000097:blood; D004591:Electrophoresis, Polyacrylamide Gel; D006801:Humans; D007118:Immunoassay; D005779:Immunodiffusion; D008077:Lipoproteins, LDL / Q000097:blood*; D008314:Malonates / Q000494:pharmacology*; D008315:Malondialdehyde / Q000494:pharmacology*; D008970:Molecular Weight
D001053:Apolipoproteins; D001055:Apolipoproteins B; D008077:Lipoproteins, LDL; D008314:Malonates; D008315:Malondialdehyde